Answers are grounded in this paper and cite their sources.
Cohort study shows dual PET/CT imaging predicts overall and progression-free survival in neuroendocrine tumors, indicating its clinical relevance.
Gastrointestinal neuroendocrine neoplasms (GI-NENs) exhibit heterogeneity in biological behavior, making it difficult to predict prognosis. We established the P Grade based on 68Ga-DOTANOC and 18F-FDG PET dual scans and evaluated the prognostic significance in patients with metastatic GI-NENs. The P Grade was categorized based on SSTRI/FDG uptake into P1 (DOTANOC positive/FDG negative), P2 (DOTANOC positive/FDG positive), and P3 (DOTANOC negative/FDG positive). Patients would be classified into P grades based on dual scan. results. Then they were divided into medical treatment and surgical group. The correlation of P Grade with progression-free survival (PFS) and overall survival (OS) was evaluated using Kaplan-Meier analysis, and performed univariate and multivariate analyzes of relevant clinicopathological variables with PFS and OS. Two hundred forty-three patients with metastatic GI-NENs were enrolled. P Grade exhibited notable statistical significance with OS and PFS in overall cohort on univariate and multivariate analysis (all p < 0.01). In surgery group, P Grade demonstrated independent predictive value for OS and PFS (all p < 0.01). In medical treatment group, P Grade demonstrated predictive value for PFS (all p < 0.01) and predicted OS (univariate P3vsP1, p < 0.01). Additional predictors of OS and PFS included WHO grade, age at diagnosis, location of primary site, sex and extrahepatic disease, they all had statistical significance with OS or PFS (p < 0.05) except sex factors. Our cohort study demonstrates that P Grade obtained by combining 68Ga-DOTANOC and 18 F-FDG PET is a significant prognostic indicator for patients with metastatic GI-NENs, regardless of whether received medical treatment or surgical resection of the primary site. This will bring a new predictive tool to clinical practice and be applicable to patients with different treatment modalities.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: